Informations générales (source: ClinicalTrials.gov)
Assessment of the Quality of Life of Patients With Lymphomas Treated With Oral Therapy (EVEREST)
Observational
University Hospital, Toulouse (Voir sur ClinicalTrials)
mai 2020
janvier 2025
29 juin 2024
The emergence of new anti-cancer drugs orally administered has revolutionized the
prognosis and modalities of management of several lymphomas over the past decade. Today,
half of patients receive oral therapy at home. Ibrutinib, acalabrutinib, idelalisib,
venetoclax and lenalidomide are oral therapies used in the treatment of Chronic Lymphoid
Leukemia, Follicular Lymphoma, Waldenström's disease and mantle cell lymphoma, in
relapsing but soon to be 1st line.
Nevertheless, clinical trials leading to marketing authorizations for these drugs were
performed in a small number of patients and very little data is available on their use in
real life conditions. Their impact on the quality of life of patients also remains to be
assessed.
The aim of this clinical research is to evaluate quality of life of patients at the
initiation of the first oral therapy and every year for 5 years. This study will also
identify factors (biological and non-biological: quality of life, shared decision-making
...) associated with a good response of patients and follow-up for the occurrence of
long-term adverse reactions (5 years).
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CH DE VERSAILLES SITE ANDRE MIGNOT | Fatiha MERABET, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Léon Bérard - 69373 - Lyon - France | Anne-Sophie MICHALLET, MD | Contact (sur clinicalTrials) | |||
| CH de Bayonne - 64100 - Bayonne - France | Julie GAY, MD | Contact (sur clinicalTrials) | |||
| CH de Perpignan - 66000 - Perpignan - France | Laurence SANHES, MD | Contact (sur clinicalTrials) | |||
| CH Le Mans - 72000 - Le Mans - France | Kamel LARIBI, MD | Contact (sur clinicalTrials) | |||
| CHU Clermont-Ferrand - 63000 - Clermont-Ferrand - France | Romain GUIEZE, MD | Contact (sur clinicalTrials) | |||
| CHU de Grenoble - 38043 - Grenoble - France | Lucile BUSSOT, MD | Contact (sur clinicalTrials) | |||
| CHU de Limoges - 87042 - Limoges - France | Natalia DMYTRUK, MD | Contact (sur clinicalTrials) | |||
| CHU de Montpellier - 34295 - Montpellier - France | Emmanuelle TCHERNONOG, MD | Contact (sur clinicalTrials) | |||
| CHU de Nîmes - 30029 - Nîmes - France | Agathe RASCALOU-WAULTIER, MD | Contact (sur clinicalTrials) | |||
| CHU de Tours - 37044 - Tours - France | Emmanuel GYAN, MD | Contact (sur clinicalTrials) | |||
| Hospices Civils de Lyon - 69495 - Pierre-Bénite - France | Emmanuelle FERRANT, MD | Contact (sur clinicalTrials) | |||
| Institut Paoli Calmettes - 13273 - Marseille - France | Luca INCHIAPPA, MD | Contact (sur clinicalTrials) | |||
| Loïc YSEBAERT - 31059 - Toulouse 9 - France | Loïc YSEBAERT, Prof. | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patients included in the PK-E3i clinical study OR
- Over the age of 18
- Patients with hemopathies and starting treatment with oral therapy (idelalisib,
ibrutinib, venetoclax, lenalidomide, acalabrutinib...)
- Be able to understand the objective and the constraints related to research
- Patient having read the information notice and the non-objection form
- Social Security affiliation
- Patients included in the PK-E3i clinical study OR
- Over the age of 18
- Patients with hemopathies and starting treatment with oral therapy (idelalisib,
ibrutinib, venetoclax, lenalidomide, acalabrutinib...)
- Be able to understand the objective and the constraints related to research
- Patient having read the information notice and the non-objection form
- Social Security affiliation
- Pregnant women
- Persons under legal protection of adults
- Patients under judicial protection